图片来源:摄图网
近日,港股上市公司德琪医药发布公告称,与翰森制药达成独家合作协议,由翰森制药负责塞利尼索在中国大陆的商业化, 德琪医药将获最高2亿元首付款及最高5.35亿元里程碑付款。
据了解,塞利尼索是德琪医药首个上市商业化产品,从Karyopharm引进,...查看全文
$Karyopharm Therapeutics Inc.(KPTI)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2018-08-17 AccNo: 0001193125-18-251663 Size: 457 KB 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ 8-K - Current report Filed: 2018-08-17 AccNo: 0001193125-18-251656 Size: 234 KBItem 1.01: Entry into a Material Definitive AgreementItem 9.01: Financial Statements and Exhibits 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ 8-K - Current report Filed: 2018-08-17 AccNo: 0001193125-18-251656 Size: 234 KBItem 1.01: Entry into a Material Definitive AgreementItem 9.01: Financial Statements and Exhibits 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-08-10,10% Owner,Chione Ltd ,卖出,702普通股, $18.50
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-08-09,10% Owner,Chione Ltd ,卖出,67474普通股, $18.51
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-08-08,10% Owner,Chione Ltd ,卖出,2800普通股, $18.61
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-08-07,10% Owner,Chione Ltd ,卖出,10602普通股, $18.60
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-08-07,CEO,Kauffman Michael ,卖出,12500普通股, $18.04
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-08-07,CEO,Kauffman Michael ,期权,12500普通股, $0.03
$Karyopharm Therapeutics Inc.(KPTI)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2018-08-07 AccNo: 0001193125-18-241301 Size: 7 MB 网页链接